Details of the Drug

General Information of Drug (ID: DMBLX7U)

Drug Name

Evinacumab

Synonyms

REGN1500; ANGPTL-1 antibody

Indication

Disease Entry	ICD 11	Status	REF
Hypercholesterolaemia	5C80.0	Approved	[1]
Elevated C-reactive protein	MA14.15	Phase 2	[2]
Familial hypercholesterolemia	5C80.00	Phase 2	[3]
------------------------------------------------------------------------------------

Affected Organisms

Humans and other mammals

ATC Code

C10AX17: Evinacumab

C10AX: Other lipid modifying agents

C10A: LIPID MODIFYING AGENTS, PLAIN

C10: LIPID MODIFYING AGENTS

C: CARDIOVASCULAR SYSTEM

ADMET Property

Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 689 mg/L [4]
Metabolism: The drug is metabolized via the catabolic pathways into smaller peptides and amino acids [4]
Vd: The volume of distribution (Vd) of drug is 4.8 L [4]

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiopoietin-related protein 3 (ANGPTL3)	TTUO98L	ANGL3_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	FDA Approved Drug Products: Evkeeza (evinacumab-dgnb) for intravenous injection